[Transfer] Chairman of the well -known pharmaceutical company and the former deputy president were arrested

Source: Sai Bailan/Mu Zhi

01

The chairman of Ji Yara was approved to be arrested

On the evening of August 12,*ST Ji Yao issued an announcement saying that he had recently received notice from the public security organs that the former chairman Sun Jun, former director and deputy general manager Wang Deheng had been approved by suspected crime.

*ST Ji medicine said that the above cases were discovered and reported to the public security organs internally. The current case is still under investigation of public security organs.

One day before, a announcement issued by the Shenzhen Stock Exchange showed that Sun Jun was in a state of loss.

The announcement stated that Sun Jun, as a shareholder of more than 5%of Ji Yaowao Holding Group Co., Ltd., was suspected of having to reduce his holdings and violations of the rules, and the Shenzhen Stock Exchange intends to report criticism for him. Because it was impossible to get in touch with Sun Jun, the deep payment was informed of the relevant matters related to the disciplinary sanction.

02

Make multiple times of negative news many times

According to the data, Sun Jun was born in August 1965. He graduated from the Party School of the Jilin Provincial Party Committee. In 2017, he began to serve as the legal representative and chairman of Jiji Pharmaceutical Holdings.

In recent years, Sun Jun has been trapped in negative news many times.

In November 2019, due to misleading statements in information disclosure and suspected "flickering reorganization", Ji Yaosheng was warned and imposed a fine of 600,000 yuan. Sun Jun was also warned and fined 300,000 yuan.

In March 2021, the Shenzhen Stock Exchange had criticized Sun Jun and Wang Deheng for criticism, and believed that the two failed to fulfill their diligence and diligence obligations. Because Sun Jun himself was not fulfilled by the company's equity repurchase obligation, he was sued by the opponent and frozen the equity.

In October 2021, Ji Pharmaceutical Holdings announced that from May 14, 2020 to March 29, 2021, Ji Yaowao Holdings did not disclose some debt involved in the debt and subsidiaries in accordance with regulations, involving a amount of RMB 634 million The proportion of the net assets of the audit assets at the end of 2019 was 168.16%. In view of the above -mentioned illegal facts and plots, the Shenzhen Stock Exchange decided to punish Sun Jun and others for criticism.

In June of this year, Sun Jun was cast at the shareholders' meeting of Ji Yaowao Holdings and officially left.

Wang Deheng, who was arrested this time, announced according to*ST Ji medicine, and he filed a resignation in October 2019, because of "personal reasons", applying for resignation of directors, deputy general managers, strategic committees, and compensation and assessment committees' positions. Essence

The former chairman and former vice president were arrested, and*ST Ji medicine itself was also troublesome.

On July 27, the company had been investigated by the Securities Regulatory Commission for suspected information disclosure. In addition,*ST Ji medicine is deeply trapped in debt, litigation and arbitration.

As of July 15, 2022,*ST Ji Pharmaceutical Company and subsidiaries have a total litigation amount involved in the deadline for 12 consecutive months, about 1.857 billion yuan; a total of 39 bank accounts from the company and subsidiaries were frozen and frozen bank account balances. A total of about 810.61 million yuan.

Ji Pharmaceutical is a well -known pharmaceutical company in Jilin. It covers the eight major health business segments such as the pharmaceutical industry, pharmaceutical commerce, medical and medical care, pharmaceutical research and development, pharmaceutical capsules, pharmaceutical packaging materials, health foods, and national defense and chemical industry.

From the perspective of the annual report of the past ten years, although the year -on -year growth rate of returning mother's net profit from 2012 to 2018 has fluctuated, the overall profit is still profitable. Beginning in 2019, Ji Yao turned to a loss, with net profit loss of 1.772 billion yuan, and the losses in 2020 and 2021 were 380 million yuan and 451 million yuan, respectively. According to this set of numbers, Ji Yao lost more than 2.6 billion yuan in three years.

At the same time, Ji Yao is suspicious of accounts receivable.

The growth rate of account receivables since 2014 is much higher than the growth rate of revenue. The bad debts of the accounting agency have been sprayed in 2019. On the one hand, the balance of the bad debt preparation of the receivables increases from the beginning of the period. On the other hand, it is difficult for clients. However, the customers disclosed that the customers who can query can receive less than 20%, and the remaining 80%cannot be verified.

In addition, since the transformation, the three major projects of Ji Yao have invested over 1 billion projects have not obtained expected returns. The consequences of direct cash are exhausted, a series of illegal punishments or negative products in this background. Later, he tried to extend mergers and acquisitions by loan, but eventually he was unable to return to heaven.

03

Shocking the acquisition of the pharmaceutical circle

In July 2019, Ji Pharmaceutical Holdings issued an announcement, intending to acquire 100%equity of amendments to the pharmaceutical industry.

According to the ranking of the National Pharmaceutical Industry Information Annual Conference at that time, the amendment of the pharmaceutical industry was ranked fourth in the top 100 Chinese pharmaceutical industry. In 2017, operating income exceeded 60 billion yuan. Jisha Holdings has not been on the list, and its operating income in 2018 is less than 1 billion yuan. Because of this, this acquisition was compared with the industry.

However, things soon happened.

On July 24, 2019, Ji Yao Holdings issued an announcement saying that after full demonstration of all parties, the reorganization plan at present does not have the conditions for implementation, and continues to promote the major uncertain factors for this major asset reorganization. After careful research, it was decided to terminate the major asset reorganization matters.

In the announcement, Ji Pharmaceutical Holdings stated that after the specific implementation rules of the major asset reorganization management measures of listed companies have matured, they will continue to promote the planning of the controlling equity transfer of listed companies and planning issuance shares. Equity matters.

Such abnormal operations attracted the attention of the regulatory authorities.

On the second day after the announcement was issued, the Management Department of the Shenzhen Stock Exchange issued a letter of attention to ask if Ji Yaosheng's reorganization may constitute the reorganization listing, not in line with the current laws and regulations, whether there is a payment capacity, etc. when applying for a suspension. During the suspension of the company, the specific argumentation matters have the cases of intentional suspension, suspension of trading, and hype. Not only that, a few days later, the pharmaceutical industry issued a statement, saying that it did not follow up with the "Lift Agreement of Integration Agreement" signed with Ji Pharmaceutical Holdings on July 24, and there was no follow -up agreement to promote the acquisition case.

On July 28, 2019, Ji Yao Holdings acknowledged in the response letter that due to the mistakes of the personnel, the content of the "Lift Agreement of the Interest Agreement" was cited in the revised draft in the draft, resulting in errors in information disclosure.

On November 27 of the same year, the Jilin Supervision Bureau of the CSRC disclosed the administrative penalty decision of four responsible persons including Jihaoxi Holdings. Sun Jun, chairman and general manager of Ji Medicine Holdings, Zhang Liang, director, secretary of the board of directors, and deputy general manager, is directly responsible for the person in charge; Zhang Zhongwei, the chief financial officer, is other direct responsible persons.

According to the facts, nature, plot, and social harm of the parties' illegal behavior, in accordance with the provisions of Article 193, paragraph 1 of the Securities Law, the Jilin Regulatory Bureau decides: RMB 600,000; warned Sun Jun and imposed a fine of 300,000 yuan; he warned Zhang Liang and imposed a fine of 300,000 yuan; he warned Zhang Zhongwei and imposed a fine of 100,000 yuan.

At this point, the acquisition of the "Snake Elephant" announced an end.

The capital market is turbulent, and industry insiders said that the situation of "tearing the face" between listed companies and former directors and supervisors is not uncommon in real life.

Under the influence of related news, as of the close of August 12,*ST Ji medicine closed at 2.29 yuan, down 2.14%, and the market value was 1.525 billion yuan. If you continue to fall again, the risk of delisting is likely to occur.

Disclaimer: This article is the content of Yaozhi.com, and the copyright of the pictures and text belongs to the original author. The purpose of reprinting is to pass more information, which does not represent the viewpoint of this platform. If the content, copyright and other issues are involved in the work, please leave a message on this platform, and we will delete it as soon as possible.

- END -